

Altus Pharmaceuticals Inc.  
Form 8-K  
September 09, 2009

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

September 3, 2009

**Altus Pharmaceuticals Inc.**

(Exact name of registrant as specified in its charter)

Delaware

0-51711

04-3573277

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(I.R.S. Employer  
Identification No.)

610 Lincoln Street, Waltham, Massachusetts

02451

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

781-373-6000

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Top of the Form**

**Item 2.05 Costs Associated with Exit or Disposal Activities.**

On September 3, Altus Pharmaceuticals Inc. (the "Company") announced a reduction in headcount of approximately 30% of its employees. The reduction in headcount is due to financial constraints. The Company has been seeking, but has been unable to date to secure, funds to finance the ongoing operations of the Company and is considering various strategic alternatives.

Employees directly affected by the restructuring plan have received notification and will be provided with severance payments.

The Company expects to record a restructuring charge of approximately \$0.5 million in the third quarter of 2009, primarily representing cash payments for severance and related expenses. Severance expenses will be paid in a lump sum.

---

**Top of the Form**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Altus Pharmaceuticals Inc.

*September 9, 2009*

By: *Thomas J. Phair, Jr.*

---

*Name: Thomas J. Phair, Jr.*

*Title: Vice President, Finance and Treasurer*